CIK 0001390478 · Non-accelerated filer<br>Smaller reporting company
SELLAS Life Sciences Group, Inc.
Sign in to watch- Ticker
- SLS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 6462005278
- Business address
- 7 TIMES SQUARE, SUITE 2503, NEW YORK, NY, 10036
- Former names
- GALENA BIOPHARMA, INC., Galena Biopharma, Inc., RXI PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-22 | SCHEINBERG DAVID A Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2024-01-22 | WOOD BARBARA A EVP, Gen. Counsel, Corp. Sec. | Grant or award | +35,000 | 117,225 | ||
| 2024-01-22 | WOOD BARBARA A EVP, Gen. Counsel, Corp. Sec. | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2024-01-22 | Kalin Katherine Bach Director | Grant or award | +6,000 | 8,500 | ||
| 2024-01-22 | Kalin Katherine Bach Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2024-01-22 | Wasman Jane Director | Grant or award | +6,000 | 10,400 | ||
| 2024-01-22 | Wasman Jane Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2024-01-22 | Francomano Robert Chief Commercial Officer | Grant or award | +20,000 | 40,918 | ||
| 2024-01-22 | Francomano Robert Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2024-01-22 | Varian John Director | Grant or award | +6,000 | 10,400 | ||
| 2024-01-22 | Varian John Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2024-01-22 | VAN NOSTRAND ROBERT L Director | Grant or award | +6,000 | 10,400 | ||
| 2024-01-22 | VAN NOSTRAND ROBERT L Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2024-01-22 | Burns John Thomas CFO | Grant or award | +47,000 | 101,927 | ||
| 2024-01-22 | Burns John Thomas CFO | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2023-12-06 | WOOD BARBARA A EVP, Gen. Counsel, Corp. Sec. | Other disposition | −4,119 | $1.08 | $4K | 82,225 |
| 2023-12-06 | Stergiou Angelos M. President and CEO | Other disposition | −12,268 | $1.08 | $13K | 217,421 |
| 2023-12-06 | Francomano Robert Chief Commercial Officer | Other disposition | −1,082 | $1.08 | $1K | 20,918 |
| 2023-12-06 | Burns John Thomas CFO | Other disposition | −2,929 | $1.08 | $3K | 54,927 |
| 2023-02-02 | WOOD BARBARA A EVP, Gen. Counsel, Corp. Sec. | Grant or award | +20,000 | 76,344 |
Page 3 of 8 · 141 trades